Journal of psychoactive drugs
June 28, 2025
Laura C Carvalho, Jorge Encantado, Hannes Kettner et al.
6 citations
A review of 103 naturalistic psychedelic studies found that most used cross-sectional surveys, ayahuasca was the most studied substance (66%), and ceremonial settings were the most common context (35.9%). Sample characteristics were widely reported but varied considerably, while specific contextual details like music were often missing. The authors call for systematic reporting standards to improve the value of real-world psychedelic research alongside clinical trials.
Acta medica portuguesa
May 2, 2025
Pedro Mota, Jorge Encantado, Laura C Carvalho et al.
1 citation
A survey of 156 Portuguese psychiatrists and psychologists found that while 59% were open to using ketamine for treatment-resistant depression, only 35.9% reported substantial knowledge of its therapeutic potential. 73% expressed concerns about inadequate professional training. Psychiatrists reported higher knowledge and openness than psychologists, and younger professionals showed greater interest in training and use. The results indicate favorable attitudes toward ketamine but highlight substantial educational gaps, suggesting that customized training based on age, sex, and professional background is needed for safe clinical integration.
Journal of psychoactive drugs
March 19, 2026
Pedro J Teixeira, Jorge Encantado, Helena D Amaro et al.
Portuguese adults who participate in ayahuasca ceremonies report good or very good health, with lower rates of chronic disease and obesity compared to the general population. They also report greater physical activity, lower alcohol consumption, and enhanced psychological well-being. Many attribute positive lifestyle changes, reduced substance use, and less reliance on prescription medication to their ayahuasca experiences. These findings align with prior research linking ayahuasca use to health and well-being, though causal pathways remain unclear.
Professional Psychology Research and Practice
February 1, 2026
Jorge Encantado, Laura C. Carvalho, Pedro Mota et al.
Psilocybin, a hallucinogen, shows promise in transforming mental health care, with 70% of participants reporting significant improvements in depression and anxiety after treatment. In a clinical study involving 100 individuals, those receiving psilocybin therapy experienced an average reduction of 60% in symptoms within three weeks. Health professionals in psychiatry and clinical psychology are increasingly exploring psychedelics as viable options for patients. This shift could reshape mental health approaches, offering hope to those struggling with traditional therapies in Portugal and beyond.
Journal of Health Psychology
December 31, 2025
Laura C. Carvalho, Jorge Encantado, Arlen C. Moller et al.
Psychedelic experiences may help people adopt healthier behaviors, according to a survey of 271 adults. Participants reported changes across 74 behaviors after their most impactful psychedelic experience. The most common changes were increases in contemplative practices (63%), time spent in nature (55%), and personally meaningful social activities (54%). Most changes were in a healthy direction. Higher perceived meaningfulness of the experience and having a set intention beforehand were significantly associated with overall healthy change. The study cannot establish causality but suggests that intention and meaningfulness are candidate mechanisms for how psychedelics might facilitate positive behavior change.
Sci Rep
November 25, 2025
Laura C. Carvalho, Jorge Encantado, Michiel van Elk et al.
Psychedelic experiences may help people adopt healthier behaviors like improved diet, more exercise, and regular meditation, according to a survey of 96 practitioners working in legal and underground settings. Practitioners reported perceived positive changes in clients' contemplative practices (61.4%), time in nature (60.1%), eating patterns (56.9%), and diet and nutrition (56%). The findings suggest that practitioners often see psychedelic experiences as linked to beneficial health behavior changes, though further research is needed to confirm these results and understand their long-term sustainability.
European Health Psychologist
August 25, 2025
Talea Cornelius, Jorge Encantado, Laura Lopes de Carvalho et al.
Psychedelic treatments show promise for improving health and well-being. This article summarizes the history of early psychedelic research and its recent renaissance. Observational studies have linked psychedelic use to healthier diet, lower rates of heart disease, and spontaneous positive changes in health-related outcomes. The importance of understanding mechanisms underlying psychedelic impacts was emphasized, as was the need for attention to the social context of psychedelic experiences. Evidence for differential impacts of psychedelic use with versus without a partner, and impacts on close relationships, was presented.
Neuropharmacology
January 1, 2026
Luisa Prochazkova, Laura C Carvalho, Natasza Marrouch et al.
Microdosing psychedelics is associated with self-reported positive changes in health behaviors, particularly in sleep, contemplative practices, physical activity, and work-life balance. A survey of 365 people with microdosing experience found that the intention to change was the strongest predictor of behavioral change, while dose, protocol, and psychiatric status were not significant predictors. Thematic analysis of qualitative responses suggested potential psychological mechanisms including improved mental health, cognitive clarity, self-awareness, self-determination, and relatedness. The findings provide an initial exploration into how microdosing might support health behavior change, but controlled studies are needed to confirm these associations.